Drugs / Edaravone Dexborneol
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT06315231 | Apr 2024 → Dec 2026 expected | cognitive impairment with or without cerebellar ataxia | Simcere Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT04817527 | Oct 2021 → Dec 2022 | ischemic stroke | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 2 | NCT04714177 | Mar 2021 → Mar 2023 | intracerebral hemorrhage | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04667637 | Feb 2021 → Oct 2022 | stroke disorder | Huisheng Chen | Completed | Missed primary |
| Phase 2 | NCT01929096 | Aug 2013 → Dec 2014 | ischemic stroke | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | Missed primary |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT06176781 | Dec 2023 → Mar 2025 | cerebral artery occlusion | Simcere Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT02430350 | May 2015 → Dec 2016 | ischemic stroke | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT07682922 | Jul 2026 → Jul 2028 expected | ischemic stroke | Xinqiao Hospital of Chongqing | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07454473 | Mar 2026 → Dec 2027 expected | — | Chuansheng Zhao | Recruiting | No outcome recorded |
| Phase 4 | NCT06645522 | Oct 2024 → Oct 2026 expected | ischemic stroke | Yi Yang | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05024526 | Apr 2021 → Dec 2022 | ischemic stroke | Lili Cao | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-01-09 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results TASTE-2 Study Published in The BMJ: Combination of Cerebral Cytoprotection and Thrombectomy Significantly Reduces Post-Stroke Disability simcere.com ↗
The results demonstrate that the addition of edaravone dexborneol, a multi-target cerebral cytoprotective agent, to standard EVT significantly increased the proportion of patients achieving functional independence at 90 days, while maintaining a favorable safety profile. |
| 2022-05-07 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results New Evidence of Sanbexin® in AIS treatment Published During ESOC 2022 simcere.com ↗
The application of edaravone dexborneol can significantly reduce the level of inflammatory factors and improve the neurological function in patients with AIS, either received or not received alteplase thrombolytic therapy. |
| 2021-09-03 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Latest Study Data of Sanbexin® Released at ESOC 2021 simcere.com ↗
Edaravone dexborneol group showed largely higher proportion of mRS score ≤1 on D90 than edaravone group (59.41% versus 51.45%; OR 1.38 [95% CI, 1.02–1.87]; P=0.036). |
| 2021-02-17 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results The Clinical Study Data for Sanbexin® was Published in the International Leading Neurology Medical Journal “STROKE” simcere.com ↗
The clinical trial data showed that edaravone and dexborneol concentrated solution for injection has better efficacy and comparable safety as compared to edaravone injection. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-09 | Jiangsu Simcere Pharmaceutical Co., Ltd. | TASTE-2 Study Published in The BMJ: Combination of Cerebral Cytoprotection and Thrombectomy Significantly Reduces Post-Stroke Disability simcere.com ↗ |
| 2022-05-07 | Jiangsu Simcere Pharmaceutical Co., Ltd. | New Evidence of Sanbexin® in AIS treatment Published During ESOC 2022 simcere.com ↗ |
| 2021-09-03 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Latest Study Data of Sanbexin® Released at ESOC 2021 simcere.com ↗ |
| 2021-02-17 | Jiangsu Simcere Pharmaceutical Co., Ltd. | The Clinical Study Data for Sanbexin® was Published in the International Leading Neurology Medical Journal “STROKE” simcere.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Edaravone dexborneol | “Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant...” PMID 33588596 ↗ Feb 202110“Edaravone Dexborneol is a novel neuroprotective agent” PMID 31709115 ↗ Apr 2019 |
| Known as | Edaravone Dexborneol Sublingual Tablets | “Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days” NCT06176781 ↗ |
| Route | Intravenous | “via intravenous infusion every 12 hours” NCT02430350 ↗ |